These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30922847)

  • 1. Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis.
    Van Bocxlaer K; Caridha D; Black C; Vesely B; Leed S; Sciotti RJ; Wijnant GJ; Yardley V; Braillard S; Mowbray CE; Ioset JR; Croft SL
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():129-138. PubMed ID: 30922847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis.
    Wijnant GJ; Croft SL; de la Flor R; Alavijeh M; Yardley V; Braillard S; Mowbray C; Van Bocxlaer K
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.
    Mowbray CE; Braillard S; Glossop PA; Whitlock GA; Jacobs RT; Speake J; Pandi B; Nare B; Maes L; Yardley V; Freund Y; Wall RJ; Carvalho S; Bello D; Van den Kerkhof M; Caljon G; Gilbert IH; Corpas-Lopez V; Lukac I; Patterson S; Zuccotto F; Wyllie S
    J Med Chem; 2021 Nov; 64(21):16159-16176. PubMed ID: 34711050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.
    Van Bocxlaer K; Gaukel E; Hauser D; Park SH; Schock S; Yardley V; Randolph R; Plattner JJ; Merchant T; Croft SL; Jacobs RT; Wring SA
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
    Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
    Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis.
    Cavalcanti de Queiroz A; Alves MA; Barreiro EJ; Lima LM; Alexandre-Moreira MS
    Exp Parasitol; 2019 Jun; 201():57-66. PubMed ID: 31004571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.
    Gupta S; Yardley V; Vishwakarma P; Shivahare R; Sharma B; Launay D; Martin D; Puri SK
    J Antimicrob Chemother; 2015 Feb; 70(2):518-27. PubMed ID: 25389223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series.
    Van den Kerkhof M; Mabille D; Chatelain E; Mowbray CE; Braillard S; Hendrickx S; Maes L; Caljon G
    Int J Parasitol Drugs Drug Resist; 2018 Apr; 8(1):81-86. PubMed ID: 29425734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antileishmanial Activities of Medicinal Herbs and Phytochemicals In Vitro and In Vivo: An Update for the Years 2015 to 2021.
    Hassan AA; Khalid HE; Abdalla AH; Mukhtar MM; Osman WJ; Efferth T
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro and In Vivo Antileishmanial Activity of Thioridazine.
    Sifontes-Rodríguez S; Mollineda-Diogo N; Monzote-Fidalgo L; Escalona-Montaño AR; Escario García-Trevijano JA; Aguirre-García MM; Meneses-Marcel A
    Acta Parasitol; 2024 Mar; 69(1):324-331. PubMed ID: 38070122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
    Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
    Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic investigation of 4-nitrophenylacetyl- and 4-nitro-1
    Santos CC; Zhang H; Batista MM; de Oliveira GM; Demarque KC; da Silva NL; Moreira OC; Ogungbe IV; Soeiro MNC
    Parasitology; 2022 Apr; 149(4):490-495. PubMed ID: 35109958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
    Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
    J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of total phenolic fraction derived from extra virgin olive oil for its antileishmanial activity.
    Koutsoni OS; Karampetsou K; Kyriazis ID; Stathopoulos P; Aligiannis N; Halabalaki M; Skaltsounis LA; Dotsika E
    Phytomedicine; 2018 Aug; 47():143-150. PubMed ID: 30166099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
    Wijnant GJ; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of the local or oral delivery of the novel naphthopterocarpanquinone LQB-118 against cutaneous leishmaniasis.
    da Cunha-Júnior EF; Pacienza-Lima W; Ribeiro GA; Netto CD; do Canto-Cavalheiro MM; da Silva AJ; Costa PR; Rossi-Bergmann B; Torres-Santos EC
    J Antimicrob Chemother; 2011 Jul; 66(7):1555-9. PubMed ID: 21531758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B.
    Velásquez AMA; Ribeiro WC; Venn V; Castelli S; Camargo MS; de Assis RP; de Souza RA; Ribeiro AR; Passalacqua TG; da Rosa JA; Baviera AM; Mauro AE; Desideri A; Almeida-Amaral EE; Graminha MAS
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507113
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Santos CC; Zhang H; Batista MM; de Oliveira GM; Demarque KC; da Silva-Gomes NL; Moreira OC; Ogungbe IV; Soeiro MNC
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.